Articles tagged with Cancer Medication
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Researchers at the University of Manchester have made a breakthrough in developing a new class of cancer drugs that target the Aurora B enzyme, which helps cells divide and can lead to uncontrolled cell growth in cancer. Early clinical trials suggest the drug's toxicity is mild, offering a revolutionary new way to treat cancer.
The University of Liverpool, Royal Liverpool University Hospital and Clatterbridge Centre for Oncology are merging to create a cancer research centre, enabling global clinical trials of new therapies. The centre will be funded by Cancer Research UK and will double the number of patients in early phase clinical trials.
The Berkeley Cancer Genome Center will use genome analysis to identify genetic changes involved in cancer. The center aims to analyze messenger RNA populations and exon-specific expression to understand cancer development.
Researchers at the University of Virginia are exploring how nutrients in broccoli prevent cancer by bonding with a specific enzyme. This enzyme is linked to inflammatory diseases and cancer, and understanding its role could lead to anti-cancer compounds.
Yale University and NFCR have established a research center to design and discover new anti-cancer drug treatments. The center will focus on developing beta-peptide inhibitors that can target abnormal protein-protein interactions, which are often present in cancer cells.
A new approach uses mouse tests to predict which chemotherapy drugs work best for each patient, offering a promising way to individualize therapy earlier in treatment. The method involves implanting tiny bits of patient tumor into mice, allowing researchers to test multiple drugs simultaneously.
Researchers at UT Southwestern Medical Center have discovered a mechanism by which cancer cells become resistant to a specific class of drugs, hemiasterlin. A mutation in a single protein renders the drug ineffective and also makes the worms resistant to several other anti-cancer drugs.
A Phase II trial of Revlimid found that over 75% of MDS patients reduced their need for transfusions, with two-thirds completely freed from transfusions. In 45% of cases, no detectable cancer was found after treatment.
Acute myelogenous leukemia (AML) patients who have multiple active molecular pathways in their blood and bone marrow samples tend to have a poorer prognosis. Targeting just one pathway is unlikely to be effective due to cross-activation, requiring the development of multi-drug therapies.
Research highlights the increased risk of suicide among breast cancer survivors for up to 30 years after diagnosis, as well as the association between hormone therapies and ovarian cancer risk. Additionally, high levels of circulating sex hormones may contribute to premenopausal breast cancer risk.
Researchers studying a lancelet, a tiny primitive fish found in Tampa Bay waters, have identified key immune system proteins that share similarities with those found in humans. The study's findings could lead to improved biodefense and biotechnology for cancer treatment and disorders like rheumatoid arthritis.
Researchers have discovered aspirin's ability to prevent blood vessel formation, a crucial step in tumor growth. By targeting this process, scientists can develop entirely new types of cancer-fighting drugs.
A study found that Tadalafil (Cialis) significantly improved erectile dysfunction in prostate cancer patients who underwent 3D-CRT. Successful intercourse rates were 48% for those taking Tadalafil, compared to 9% for placebo group.
Researchers found that a defective version of the NPRL2 tumor suppressor gene makes lung cancer cells resistant to cisplatin, a common chemotherapy drug. Gene therapy targeting this gene may restore sensitivity to cisplatin, offering new hope for treating resistant lung cancer.
A Stanford study finds that the cancer drug Gleevec, used to combat leukemia and gastrointestinal cancers, may also be effective in treating rheumatoid arthritis. The researchers tested Gleevec on mice with a condition similar to human rheumatoid arthritis and found it almost completely prevented disease development.
A new genetic 'roadmap' tool connects human diseases with potential drugs, revealing potential applications in cancer and other diseases. The Connectivity Map uses genomic signatures to predict molecular actions of novel therapeutic compounds and suggest ways existing drugs can be newly applied.
Researchers have unveiled a new systematic approach to drug discovery that matches diseases with potential treatments using gene signatures. The 'Human Connectivity Map' allows scientists to compare disease signatures with those of treated cells, identifying effective treatments for cancer, obesity and Alzheimer's disease.
The journal features articles on integrative cancer therapies combining conventional and alternative medicine. It has generated significant media attention and will receive its first Impact Factor in 2008 Journal Citation Reports.
The Starr Cancer Consortium aims to coordinate research efforts among five renowned institutions to understand and treat cancer. The collaboration will focus on developing new technologies, diagnostic approaches, and treatments for various forms of the disease.
Researchers have found that a class of cancer drugs can restore skeletal muscle mass and prevent decline in muscular dystrophy. Treatment with histone deacetylase inhibitors like Trichostatin A improved muscle function and resistance to degeneration in dystrophic mice.
A potential diagnostic marker indicates anti-angiogenic drugs' effectiveness by measuring a decrease in circulating endothelial cells. Anti-angiogenic drugs target tumor blood vessels, starving them of oxygen and nutrients.
Researchers at Thomas Jefferson University have discovered a new way to sidestep gleevec resistance in leukemia cells. By reactivating the protein C/EBP-alpha, they found that leukemia development is halted. This discovery could lead to new treatment strategies for leukemias resistant to gleevec and other cancers.
Researchers at Salk Institute discover that cancer cells use NF-kB survival factor to stay alive when attacked by chemotherapeutic drugs. This finding suggests a strategy to enhance the effectiveness of rapamycin-based therapies by inhibiting NF-kB signaling.
Researchers are using the tiny fruit fly Drosophila to identify genes that impact on the spread of human cancer cells. By combining genetic screens with functional analysis in human cell culture models, they aim to discover novel proteins involved in cell migration and invasion.
A Purdue University researcher has shed light on the details of one mechanism by which targeted drug therapy is achieved. The understanding of how to deliver and unload a cancer drug can be extrapolated to other diseased cells, including those involved in arthritis, multiple sclerosis, and Crohn's disease.
V. Craig Jordan's research has led to breast cancer prevention drugs like tamoxifen and raloxifene; the new grant aims to develop a treatment model to reverse resistance to anti-estrogen therapy, facilitating access to new breast cancer therapeutic drugs.
A study found that cyclin D1 gene overexpression is associated with better survival outcomes and increased sensitivity to the cancer-fighting drug bortezomib in breast cancer patients. This is because it suppresses the activity of another gene, STAT3, which promotes cell growth and prevents tumor cells from dying.
A study led by Pasi Jänne found that a single mutation in the EGFR protein can cause drug resistance in non-small cell lung cancer. The investigation demonstrated that even tiny quantities of this mutation can lead to resistance, challenging current treatment strategies.
Researchers at Ohio State University have discovered how a chemotherapy drug aids an anti-cancer virus in targeting brain tumors. The study found that the drug slows immune cells' activity, allowing the virus to spread and kill more cancer cells. This may lead to new treatment options for incurable human brain tumors.
Researchers have identified a genetic profile indicating chromosomal instability as predictive of clinical outcome in various cancer types. This signature was found to predict poor clinical outcome in 12 populations studied, making it a potential diagnostic tool for identifying aggressive cancers.
Finasteride increases PSA testing's ability to detect prostate cancer with higher sensitivity and accuracy, according to a study published in the Journal of the National Cancer Institute. The study found that men taking finasteride had improved PSA test performance compared to those taking a placebo.
A new study finds that drinking carbonated soft drinks is not linked to esophageal cancer or cardia adenocarcinoma. Additionally, bortezomib has been shown to inhibit the growth of neuroblastoma cells, a childhood tumor type.
A study found that 9.9% of chemotherapy medications for children with acute lymphoblastic leukemia were prescribed or administered incorrectly. The errors may have put patients at risk of relapse or overdose-related complications.
A new experimental RNA-based drug has been shown to kill prostate cancer cells by targeting specific genes and inducing cell death. The treatment, developed at Duke University Medical Center, was tested in mice and found to shrink tumor size by half without causing any side effects.
Researchers discovered a key component in the insulin pathway that contributes to metabolic syndrome and insulin resistance. The study found that reducing this gene's function can lower glucose and lipid levels and even extend lifespan.
Researchers discovered that JAK/STAT signaling can change the genetic packaging of DNA, leading to the activation of previously silenced genes and contributing to cancer. This finding suggests a new mechanism for cancer development and has implications for cancer treatment.
A phase III study found that adding topotecan to standard chemotherapy for ovarian cancer does not increase overall survival or reduce cancer recurrence. The treatment instead leads to more blood-related toxicities and infections.
A Phase III clinical trial at St. Jude Children's Research Hospital shows that erythropoietin (EPO) increases hemoglobin levels in anemic children with cancer, reducing the need for red blood cell transfusions and improving their quality of life.
MDM2 overproduced leads to unbalanced p53 regulation, promoting cancer cell growth. The study identifies protein fragments binding to MDM2, inhibiting its destructive effect on p53.
Researchers found that tamoxifen does not significantly reduce mortality in women at lower risk of breast cancer. For high-risk women, taking tamoxifen can be expensive with a $1.3 million price tag per year of life saved in the US market.
A new study finds that tamoxifen has little impact on mortality rates for most high-risk women, with life expectancy improving only at higher breast cancer risks. The high cost of tamoxifen further reduces its utility as a cancer prevention drug in the US.
A study by Thomas Force and his team found that Gleevec, a 'miracle' cancer drug, can cause heart failure in patients with CML due to its effect on the Abelson tyrosine kinase protein. The researchers also discovered that second-generation Gleevec drugs may have similar toxicities.
A team of researchers has designed tools to accelerate interpretation and potential use of human genome project information. The Joint Center for Molecular Modeling will support scientists in developing innovative software for improving protein structure prediction quality.
Researchers developed a new strategy to identify genetic mutations that drive cancerous growth by analyzing proteins instead of genes. This approach allows for rapid identification of molecular abnormalities vulnerable to specific drug treatments, enabling personalized medicine and potential targeted therapies.
Researchers at Thomas Jefferson University have identified proepithelin as a crucial protein in the spread of bladder cancer. The study found that proepithelin promotes migration and invasion of bladder cancer cells, suggesting it could be a potential target for new drugs.
Researchers at Ohio State University found that interleukin 21 boosts natural killer cell activity, attacking and destroying Herceptin-coated breast cancer cells. This could lead to increased patient response rates with the existing drug.
Researchers at the University of Pennsylvania School of Medicine used molecular imaging techniques to discover small molecule compounds that can restore normal p53 function in cancer cells, killing human tumor cells. The findings emphasize the growing role of imaging technology in individualized cancer treatments.
Researchers have developed an enzyme inhibitor that targets betaine-homocysteine-S-methyltransferase (BHMT), slowing cancer growth by reducing methionine production. The BHMT inhibitors show promise as a potential treatment for cancer, with the possibility of enhancing efficacy when combined with other drugs.
Researchers at the University of Minnesota have discovered a novel class of tumor-targeting compounds that inhibited tumor growth by up to 80 percent in animal studies. The compounds, designed to mimic anti-angiogenic proteins, show promise in treating solid and liquid tumors, including those found in leukemia and other blood cancers.
Researchers discover that a specific gene mutation increases gene activity to speed up the internal clock, contrary to previous beliefs. This finding has significant implications for developing treatments for circadian rhythm disorders such as depression and insomnia.
The drug, Dz13, targets c-Jun, a master regulator gene involved in diseases such as cancer and inflammation. In pre-clinical models, it has shown effectiveness in treating skin cancers and eye diseases like AMD.
The publication of consensus recommendations for FDG PET usage is expected to reduce variability in clinical trials, leading to shorter trials and improved treatment outcomes. The guidelines provide a valuable reference for incorporating PET into clinical trials and promoting drug development.
The Lancet highlights the case of CancerBACUP, a UK charity that accepted funding from drug manufacturer for trastuzumab, yet failed to disclose this in press releases. The charity's failure undermines its credibility and raises questions about its true interests.
The HHMI Physician-Scientist Early Career Award program provides flexible funding and time for young physicians to pursue research careers. Thirteen awardees have made impressive contributions to various fields, including genomics, proteomics, and cancer research.
Researchers found that a gene-regulating enzyme is targeted by certain monoamine oxidase inhibitors used to treat depression. These drugs, such as tranylcypromine, may also have anti-cancer activity due to their ability to inhibit the growth of cancer cells.
The introduction of Gardasil in the USA is proving problematic due to social and cultural resistance. The Bill and Melinda Gates Foundation has donated $27.7 million to PATH to research introducing the vaccine in developing countries, where Merck and GSK can assist by identifying cultural barriers.
A study by Johns Hopkins Medicine found that tracking computer-based error reports can improve patient safety. The researchers analyzed 1,010 medication errors and found that nearly one-third of all errors occurred with anti-infective medications.
Sheryl Tsai receives $240,000 to pursue her work on polyketide synthases, enzymes that produce natural products used in pharmaceuticals. Her research aims to develop new drugs for cancer and other diseases.
Scientists at Rice University and M.D. Anderson Cancer Center have developed a method to load multiple anticancer drugs into a single antibody, increasing the effectiveness of chemotherapy. The use of buckyballs, soccer ball-shaped molecules of pure carbon, allows for the creation of targeted therapeutics with unique properties.
A new nationwide study found that cyclophosphamide improved breathing, lung function, quality of life, functional disability, and skin thickness in patients with scleroderma. The findings will help researchers develop new drug therapies and better understand the disease's development.